572 related articles for article (PubMed ID: 19585490)
1. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
Zolochevska O; Figueiredo ML
Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
[TBL] [Abstract][Full Text] [Related]
2. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
5. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
6. The androgen receptor and prostate cancer invasion.
Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E
Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012
[TBL] [Abstract][Full Text] [Related]
7. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
8. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.
Zou JX; Zhong Z; Shi XB; Tepper CG; deVere White RW; Kung HJ; Chen H
Prostate; 2006 Oct; 66(14):1474-86. PubMed ID: 16921507
[TBL] [Abstract][Full Text] [Related]
9. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
10. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
11. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.
Qin HR; Iliopoulos D; Nakamura T; Costinean S; Volinia S; Druck T; Sun J; Okumura H; Huebner K
Mol Cancer Res; 2007 Sep; 5(9):957-65. PubMed ID: 17704139
[TBL] [Abstract][Full Text] [Related]
12. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
13. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines.
Diallo JS; Péant B; Lessard L; Delvoye N; Le Page C; Mes-Masson AM; Saad F
Prostate; 2006 Sep; 66(12):1245-56. PubMed ID: 16705740
[TBL] [Abstract][Full Text] [Related]
14. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
15. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
17. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
Cohen MB; Rokhlin OW
J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
20. A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression.
Vijayvargia R; May MS; Fondell JD
Cancer Res; 2007 May; 67(9):4034-41. PubMed ID: 17483314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
